Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2000

View Archived Issues

Scios reviews developments in third quarter

New developments at Elan during the third quarter

Brain distribution of KW-6002 examined in vitro and in vivo; metabolism in rats also studied

KMD-3213: binding kinetics and pharmacological activity correlated in vivo

Sanofi-Synthelabo recovers full rights to oxaliplatin for the U.S.

Bendamustine considered of little therapeutic value in heavily pretreated germ cell cancer

New market launch for Seroquel

Repligen's soluble form of CTLA4 cleared for phase II trials

ASA 2000: Ono-5046 protects against I/R-induced renal injury via effect on leukocyte activation

MGI Pharma selects pancreatic cancer as initial target in phase III trial of irofulven

Interaction of MCI-154 and isoflurane on myocardial contractility and hemodynamics

Bayer's Avelox approved in Canada

Two Nobex drug candidates to be supported by NIH grants

NIH grant to support Avant's herpes vaccine development

Cyclic tetrapeptide antitumor agents designed at Japan Energy

Medarex and ZymoGenetics unite to develop human antibodies

International patent issued recently for new CRF antagonists from Taisho

C&C describes new series of thrombin inhibitors

Researchers at Suntory present new nAChR agonists useful for CNS disorders

Novel dopamine D2 receptor agonists synthesized at AHP

EGF receptor tyrosine kinase inhibitors reported to be useful for PET imaging

Schering AG discloses new beta-carbolines useful in Rx of anxiety and cognition disorders

Delta opioid receptor ligands and potential therapeutic uses

Phase III trial of lupus drug LJP-394 begins

Ariad receives GVHD treatment patent

Cancer therapy activates multiple apoptosis pathways

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...